Physician profile
Harry Berkowitz
NPI 1164436515
$3,452.74
in general payments reported to CMS, 2019-2025
28 companies · $750 in 2025
The $750 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $182 · 2021: $124 · 2022: $398 · 2023: $669 · 2024: $898 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,316.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $898.95 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $280.00 | 2025 | Caplyta |
| Novo Nordisk INC | $278.02 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.72 | 2019-2020 | |
| Intuity Medical INC | $232.00 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Corcept Therapeutics | $172.85 | 2024 | Korlym |
| Intra-Sana Laboratories | $172.04 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Otsuka America Pharmaceutical, INC. | $150.00 | 2025 | Rexulti |
| Pharmacosmos Therapeutics INC. | $125.00 | 2023 | Monoferric |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.28 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Sanofi-Aventis U.S. LLC | $91.35 | 2019 | |
| Amarin Pharma, INC. | $87.79 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.90 | 2023-2024 | Glassia, Aralast |
| Abbvie INC. | $64.07 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $59.54 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $57.76 | 2024-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $47.35 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Shield Therapeutics INC | $46.31 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $39.38 | 2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $38.49 | 2021 | |
| Gilead Sciences, INC. | $32.71 | 2025 | |
| Allergan, INC. | $29.38 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.89 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $16.66 | 2023 | Breztri |
| Antares Pharma, INC. | $16.61 | 2022 | |
| Astellas Pharma US INC | $15.66 | 2024 | Veozah |
| Arbor Pharmaceuticals, INC. | $13.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.